NCT02522611 2026-01-23
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
4 trialsNCT05067257 2024-03-18
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Sorrento Therapeutics, Inc.
Phase 2 Suspended
NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
NCT03226574 2020-10-20
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 1 Completed